| Literature DB >> 24171937 |
Morten Olaussen1, Oeystein Holmedal, Morten Lindbaek, Soeren Brage, Hiroko Solvang.
Abstract
OBJECTIVES: To evaluate the current evidence for the efficacy of corticosteroid injection and non-electrotherapeutic physiotherapy compared with control for treating lateral epicondylitis.Entities:
Keywords: SPORTS MEDICINE
Year: 2013 PMID: 24171937 PMCID: PMC3816235 DOI: 10.1136/bmjopen-2013-003564
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Outline of the selection process.
Quality rating of studies by assessing internal and external validity with the PEDro scale
| Study | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEDro criterion | Bisset | Coombes | Hay | Price | Smidt | Toker | Lindenhovius | Newcomer | M-Silvestrini | Peterson | Selvanetti | Kochar | Tonks | |
| 1 | Eligibility criteria were specified | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2 | Participants were randomly allocated to groups | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3 | Allocation was concealed | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 |
| 4 | The groups were similar at baseline regarding the most important prognostic indicators | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 5 | There was blinding of all participants | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| 6 | There was blinding of all therapists who administered the therapy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| 7 | There was blinding of all assessors who measured at least one key outcome | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | Measures of at least one key outcome were obtained from more than 85% of the participants initially allocated to groups | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| 9 | All participants for whom outcome measures were available, received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by ‘intention to treat’ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| 10 | The results of between-group statistical comparisons are reported for at least one key outcome | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11 | The study provides point measures as well as measures of variability for at least one key outcome | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total PEDro score | 8 | 8 | 8 | 8 | 8 | 6 | 9 | 8 | 6 | 7 | 7 | 4 EXCLUDED | 4 EXCLUDED | |
Demographics, treatments and outcome measures in the eleven included studies
| Study and year setting and sample size | Women (percentages) | Age (mean if not otherwise stated) | Duration of discomforts (weeks) | Treatment groups | Control group | Outcome measures (excerpts) | Follow-up (weeks) |
|---|---|---|---|---|---|---|---|
| Bisset | 35 | 47.6 (SD 7.8) | 22 (median) | (1) 10 mg Triamcinolone and 1 mL lidocaine against the most painful point repeated after 2 weeks | Information, wait-and-see | Improvement on 6-point Likert-scale | 52 |
| Coombes | 38 | 49.7 (SD 8.1) | 16 (median) | (1) One injection of 1 mL triamcinolone 10 mL/mL and 1 mL lignocaine 1% against site of greatest palpable tenderness at the common extensor origin | Placebo injection 0.5 mL 0.9% isotonic saline | Improvement on 6-point Likert-scale | 52 |
| Hay | Group 1:41 | Age ≥45:(percentages) | 9 (mean) | (1) One injection of methylprednisolone 20 mg and 0.5 mL 1% lignocaine towards tender spot | Placebo tablets | Improvement on 5-point Likert-scale | 52 |
| Price | Group 1:48 | Group 1:47 | Group 1:20 (6–150) | (1) Hydrocortisone 25 mg and 1% lidocaine against tender point (2 mL fluid) (55% received 2 injections) | 2 mL 1% lidocaine against tender point | Pain on VAS | 24 |
| Smidt | Group 1:55 | Group 1: 47 | Group 1:11 (8–16) | (1) 10 mg triamcinolone and 1 mL lidocain against all tender points up to three injections | Wait-and-see (some were prescribed naproxen orally 1000 mg daily) | Improvement on 6-point Likert scale | 52 |
| Toker | 43 | 45 (range 19–72) | Not stated | One injection of 1 mL metylprednisolon and 1 mL prilocain with oral diklofenac three tablets (dose not stated) and etofenamate topically | Oral diklofenac three tablets (dose not stated) and etofenamate topically | Perceived absence of pain | 4 |
| Lindenhovius | Treatment: 63 | Treatment: 50±8 | Treatment: 12±4 (2–20) | 4 mg dexamethasone and 10 mg lidocaine (2 mL fluid) against the most tender spot, fanning of the needle. One injection—but 6 of 64 got 2 injections | 10 mg lidocain, 2 mL fluid total | DASH questionnaire* | 26 |
| Newcomer | 51 | Treatment: 46.0± 7.0 | Treatment: 3.2 (mean) SD 0.8 | One injection of 5 mL 4:1 0.25% bupivacaine and 6 mg/mL β-methasone against tender point. Home exercises consisting of ice massage, wrist stretching and progressive eccentric and concentric exercises | Placeboinjection of 5 mL bupivacaine | Pain on VAS | 26 |
| M-Silvestrini | 47 | 45.5±7.7 | More than 12 | (1) Concentric strengthening 3×10 repetitions once daily and wrist stretching twice daily for 6 weeks | Wrist stretching twice daily for 6 weeks | PFGS | 6 |
| Peterson | 42 | 48 | Treatment: 107 | Three-month daily exercise regime performed at home with progressively increasing load on the extensor muscles | Information, wait-and-see | Pain on VAS during contraction and during elongation of forearm muscles | 12 |
| Selvanetti | Treatment: 45 | Treatment: 41.3 | Treatment: 28 (8–40) | 4 weeks home-exercise after instruction from physiotherapist consisting of stretching and eccentric exercise | Sham ultrasound 20 sessions | Ko scoring system (includes clench test, Thomsen test and pain) | 44 (24–56) |
*DASH questionnaire is an upper extremity specific health status measure.
DASH,Disability of the Arm, Shoulder and Hand; PFGS, Pain-Free Grip Strength;PRFEQ, Patient-rated Forearm Evaluation Questionnaire; PRTEE questionnaire, Patient-Rated Tennis Elbow Score, VAS, Visual Analogue Scale.
Effect size of improvement rate, reduction in pain and increase in grip strength for corticosteroid injection
| Short term | Intermediate term | Long term | |
|---|---|---|---|
| 4–12 weeks | 26 weeks | 52 weeks | |
| CSI vs no intervention or NSAIDs | |||
| Bisset | 2.94 (1.90 to 4.45)* | 0.55 (0.41 to 0.73)* | 0.75 (0.62 to 0.90)* |
| Coombes | 7.32 (2.83 to 18.94)* | 0.68 (0.50 to 0.92)* | 0.91 (0.77 to 1.06) |
| Hay | 1.60 (1.18 to 2.17)* | 0.77 (0.60to 0.98)* | 1.07 (0.88 to 1.30) |
| Smidt | 2.86 (1.96 to 4.16)* | – | 0.84 (0.68 to1.02) |
| Toker | 2.27 (1.04 to 4.97) * | – | – |
| Pooled | – | 0.66 (0.53 to 0.81) * | 0.87 (0.73 to 1.04) |
| >65% | p | p | |
| CSI vs no intervention or NSAIDs | |||
| Bisset | −1.43 (−1.83 to −1.04)* | 0.40 (0.04 to 0.76)* | 0.27 (−0.08 to 0.62) |
| Coombes | −2.14 (−2.68 to −1.60)* | 0.16 (−0.28 to 0.59) | 0.08 (−0.35 to 0.52) |
| Hay | −1.05 (−1.45 to−0.66)* | 0.42 (0.04 to 0.80)* | 1.35 (0.94 to 1.76)* |
| Smidt | −1.49 (1.89 to−1.08)* | 0.27 (−0.09 to 0.63) | 0.15 (−0.20 to 0.51) |
| Toker | −1.14 (−2.07 to −0.22)* | – | – |
| Pooled | −1.43 (−1.64 to −1.23)* | 0.32 (0.13 to 0.51)* | |
| Heterogeneity | p | p | |
| CSI vs lidocaine injection | |||
| Lindenhovius | −0.25 (−0.74 to 0.24) | 0.27 (−0.30 to 0.84) | – |
| Price 1 | −1.06 (−1.63 to −0.49)* | 3.13 (2.31 to 3.95)* | – |
| Price 2 | −3.37 (−4.20 to −2.54)* | 1.55 (0.93 to 2.17)* | |
| Pooled | |||
| Heterogeneity | – | ||
| Heterogeneity | – | ||
| CSI, exercise and stretching vs exercise and stretching | |||
| 0.16 (−0.49 to 0.81) | −0.37 (−1.04 to 0.30) | – | |
| CSI vs no intervention or NSAIDs | |||
| −1.42 (−1.82 to −1.03)* | −0.38 (−0.74 to −0.02)* | −0.36 (−0.72 to 0.002) | |
| No pooling | |||
| CSI vs lidocaine injection | |||
| Lindenhovius | −0.19 (−0.68 to 0.30) | 0.07 (−0.50 to 0.64) | |
| Price 1 | −0.06 (−0.59 to 0.48) | −0.98 (−1,58 to −0.38)* | |
| Price 2 | 2.31 (1.62 to 3.00)* | −0.86 (−1.44 to −0.29)* | – |
| Pooled | – | – | |
| >65% | >65% | ||
| – | −0.48 (−0.73 to −0.24)* | – | |
| Heterogeneity | >65% | p=0.04, I2=64% | |
| CSI, exercise and stretching vs exercise and stretching | |||
| Newcomer† | −0.17 (−0.61 to 0.27) | – | – |
*Statistically significant (p<0.05); Price 1: hydrocortisone versus lidocaine and change in pain-free grip strength and Price 2: triamcinolone versus lidocaine.
†The values for Newcomer are given as change in pain.
CSI, corticosteroid injection; NSAIDS, non-steroidal anti-inflammatory drugs; RR, relative risk; SMD, standard mean difference.
Figure 2Forest plot of effect sizes for corticosteroid injection.
Effect sizes of treatment effects for non-electrotherapeutic physiotherapy
| Short term | Intermediate term | Long term | |
|---|---|---|---|
| 4–12 weeks | 26 weeks | 52 weeks | |
| Overall improvement RR (relative risk) (95% CI)—RR>1 favours treatment | |||
| Bisset | 2.44 (1.54 to 3.85)* | 0.94 (0.78 to 1.12) | 1.04 (0.93 to 1.15) |
| Coombes | 4.00 (1.46 to 10.94)* | 1.06 (0.89 to 1.28) | 1.08 (0.99 to 1.18) |
| Pooled | 2.75 (2.09 to 3.62)* | 0.99 (0.75 to 1.30) | 1.05 (0.75 to 1.49) |
| Heterogeneity | p | p=0.33 I2=0% | p |
| Pain SMD (standardised mean difference; 95% CI)—negative value favours treatment | |||
| Bisset | −0.63 (−0.99 to −0.27)* | −0.25 (−0.62 to 0.11) | −0.38 (−0.74 to −0.03)* |
| Coombes | −1.27 (−1.74 to −0.79)* | 0.00 (−0.44 to 0.44) | 0.00 (−0.44 to 0.44) |
| Pooled | − | −0.15 (−0.43 to 0.13) | −0.23 (−-0.51 to 0.04) |
| Heterogeneity | >65% | p=0.39 I2=0% | p |
| Pain-free grip strength ratio affected/ unaffected arm SMD (95%) | |||
| 0.76 (0.39 to 1.13)* | 0.20 (−0.47 to 0.56) | 0.17 (–0.18 to 0.52) | |
| DASH score (0−100, 100 most discomforts, negative value favours treatment) SMD (95% CI) | |||
| Peterson | −0.03 (−0.47 to 0.40) | – | |
| Pain on maximum voluntary contraction SMD (95% CI)—negative value favours treatment | |||
| Peterson | −0.30 (−0.74 to 0.14) | – | |
| Pain on maximum muscular elongation SMD (95% CI)—negative value favours treatment | |||
| Peterson | −0.24 (−0.68 to 0.19) | -– | |
| DASH score (0−100, 100 most discomforts, negative value favours treatment) SMD (95% CI) | |||
| M-Silvestrini | −0.07 (−0.46 to 0.60) | – | |
| Pain SMD (95% CI)—negative value favours treatment | |||
| M-Silvestrini | −0.04 (−0.57 to 0.49) | – | |
| Pain-free grip strength affected arm SMD (95%) | |||
| M-Silvestrini | −0.26 (−0.79 to 0.27) | – | |
| Concentric exercise and stretching vs stretching | |||
| DASH score (0−100, 100 most complaints, negative value favours treatment) SMD (95% CI) | |||
| M-Silvestrini | 0.14 (−0.39 to 0.68) | – | |
| Pain SMD (95% CI)—negative value favours treatment | |||
| M-Silvestrini | 0.41 (−0.13 to 0.95) | – | |
| Pain-free grip strength affected arm SMD (95% CI) | |||
| M-Silvestrini | −0.34 (−0.88 to 0.20) | ||
| Selvanetti | – | − | 23.39 (3.38 to 161.70)* |
| Pain on Ko scale (larger value means less pain) SMD (95% CI) | |||
| Selvanetti | 4.45 (3.51 to 5.40)* | −4.65 (3.68 to 5.63) * | |
| Grip strength on Ko scale (larger value means greater strength) SMD (95% CI) | |||
| Selvanetti | 3.16 (2.40 to 3.92)* | −3.65 (2.82 to 4.47) * | |
*Statistically significant (p<0.05).
Figure 3Forest plot of effect sizes for non-electrotherapeutic physiotherapy.